ライフサイエンスコーパス: e antigen

1 infected (all in recipients positive for HBV e antigen).

2 ated with a higher prevalence of hepatitis B e antigen.

3 which is proteolytically processed to yield e antigen.

4 tibodies to lipopolysaccharide and hemolysin E antigen.

5 ntibodies compared to mice immunized with WT E antigen.

6 s B surface antigen, HBV DNA, or hepatitis B e antigen.

7 infection who were negative for hepatitis B e antigen.

8 CI, 22.0%-31.9%) was positive to hepatitis B e antigen.

9 ly believed to discriminate between core and e-antigen.

10 antigens and the RHCE gene encodes the c and E antigens.

11 rcentage of cells expressing DEN-2 envelope (E) antigen 7 days after challenge.

12 sponders were still negative for hepatitis B e antigen (94% vs. 40%; P < 0.001) and hepatitis B surfa

13 The primary outcomes were hepatitis B (HB) e antigen (Ag) and HBV-DNA clearance (as measures of eff

14 lanation for the distinction between cAg and e-antigen (an unassembled form of capsid protein) and an

15 ia, a simplified algorithm using hepatitis B e antigen and alanine aminotransferase (the Treatment El

16 The surgeon was positive for hepatitis B e antigen and had a high serum HBV DNA concentration (15

17 s B viral surface antigen, hepatitis B viral e antigen and HBV replication.

18 d hepatitis B virus DNA testing; hepatitis B e antigen and hepatitis B e antibody were tested <50% of

19 s evidenced by the loss of serum hepatitis B e antigen and hepatitis B virus (HBV) DNA.

20 gic, and functional features between the PAL-E antigen and NRP-1 support our interpretation.

21 (defined by the absence of serum hepatitis B e antigen and serum HBV DNA) at week 52 of treatment.

22 in vitro, causing a reduction of hepatitis B e antigen and specific loss of cells expressing viral RN

23 esponded to therapy with loss of hepatitis B e antigen and viral DNA from serum.

24 riol inhibited the secretion of hepatitis B "e" antigen and hepatitis B surface antigen (HBV-encoded

25 e-antigen, nor did they discriminate between e-antigen and dimers of dissociated core antigen capsids

26 ercent to 33% experience loss of hepatitis B e antigen, and 53% to 56% have a histologic response.

27 e (ALT) levels, disappearance of hepatitis B e antigen, and improvement in liver histology.

28 Serum levels of HBV surface antigen and HBV e antigen, and numbers of HBV antigen-positive hepatocyt

29 the appearance of antibodies to hepatitis B e antigen (anti-HBe) at the end of PEG-IFN therapy (HBeA

30 cohort B: 23 antibodies against hepatitis B e antigen (anti-HBe)-positive patients who stopped treat

31 serology was measured, including hepatitis B e antigen, antibodies to hepatitis B e antigen, antibodi

32 titis B e antigen, antibodies to hepatitis B e antigen, antibodies to hepatitis D, hepatitis B virus

33 ysis of tryptic peptides to identify the PAL-E antigen as a secreted form of vimentin.

34 ral replication (detectable serum HBV-DNA or e antigen) at the time of transplant have a higher rate

35 nd 45 (87%) had detectable serum hepatitis B e antigen before treatment.

36 regards to phenotypic antibody properties (i.e., antigen-binding, affinity, and epitope specificity).

37 ne activation and that instantaneous loss of e-antigen by either mechanism is associated with least l

38 ction and propose mechanisms for hepatitis B e-antigen clearance, subsequent emergence of a potent ce

39 We also showed that the PAL-E antigen colocalizes with NRP-1 staining in endothelial

40 was proven by the formation of a 2:1 Fab e6-e-antigen complex.

41 HBV surface antigen and 26 days prior to HBV e antigen detection.

42 pressed ubiquitously, our examination of HLA-E antigen distribution indicated that it is detectable o

43 ent forms of the HBV core antigen (HBcAg) or e antigen (eAg) were found to induce antigen-specific ma

44 The prM/E antigens expressed in lettuce chloroplasts should offe

45 the AUG codon severely impaired hepatitis B e antigen expression (P < 0.001).

46 re promoter mutations diminished hepatitis B e antigen expression in an additive manner.

47 Reduction in hepatitis B e antigen expression may contribute to accelerated seroc

48 was to determine their effect on hepatitis B e antigen expression.

49 hether this double mutation is important for e antigen expression.

50 and -7 (in the residual propeptide) in the "e-antigen" form of the capsid protein and has implicatio

51 tect the presence of the precore protein and e antigen from CID variants.

52 xpression of a model hepatitis B virus (HBV) e antigen fused to an IgG Fc fragment.

53 ansferase levels, HBV DNA level, hepatitis B e antigen (HBeAg) and antibody (anti-HBe), hepatitis B s

54 induced pronounced reductions in hepatitis B e antigen (HBeAg) and HBsAg, associated with a transient

55 positive, and 61% had detectable hepatitis B e antigen (HBeAg) and HBV DNA when treatment was begun.

56 TLRs) on spontaneous hepatitis B virus (HBV) e antigen (HBeAg) and hepatitis B s antigen (HBsAg) sero

57 rum hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg

58 mutants and studied kinetics of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg

59 Spontaneous seroclearance of hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV) DNA undete

60 IMPORTANCE Expression of hepatitis B e antigen (HBeAg) and overproduction of HBsAg by wild-ty

61 (PD-L)1, and the suppression of hepatitis B e antigen (HBeAg) and surface antigen (HBsAg) biosynthes

62 cal hepatitis B virus core antigen (HBc) and e antigen (HBeAg) and, additionally, the precore-related

63 ous or antiviral therapy-related hepatitis B e antigen (HBeAg) clearance.

64 nfidence interval [CI] 1.7-3.2), hepatitis B e antigen (HBeAg) clearance/loss (RR = 2.1, 95% CI 1.5-3

65 100 mg/d) in 24 patients who had hepatitis B e antigen (HBeAg) despite 1 to 3 months of prior therapy

66 ong the other 60 patients, 1 showed positive e antigen (HBeAg) early after transplantation, and 2 (1

67 al genome replication and reduce hepatitis B e antigen (HBeAg) expression.

68 a precore/core protein, which is secreted as e antigen (HBeAg) following removal of precore-derived s

69 Secretion of the hepatitis B virus (HBV) e antigen (HBeAg) has been conserved throughout the evol

70 s. 23 percent, P<0.001), loss of hepatitis B e antigen (HBeAg) in serum (32 percent vs. 11 percent, P

71 y); 9 patients were positive for hepatitis B e antigen (HBeAg) in the immune-tolerant phase and were

72 Hepatitis B e antigen (HBeAg) is a secreted version of hepatitis B v

73 (HBV) infection, persistence of hepatitis B e antigen (HBeAg) is associated with clinical progressio

74 The function of the hepatitis B e antigen (HBeAg) is largely unknown because it is not r

75 Hepatitis B e antigen (HBeAg) loss by week 192 was associated with d

76 A predict a higher likelihood of hepatitis B e antigen (HBeAg) loss in patients with chronic hepatiti

77 Undetectable serum HBV DNA and hepatitis B e antigen (HBeAg) loss were significantly more likely at

78 e-third of patients with typical hepatitis B e antigen (HBeAg) positive chronic hepatitis B, but a le

79 CHB, among whom, 28.6% were also hepatitis B e antigen (HBeAg) positive.

80 higher in subjects with maternal hepatitis B e antigen (HBeAg) positivity and who received HBIG off-s

81 epatitis B virus (HBV) genotype, hepatitis B e antigen (HBeAg) presence, persistently high levels of

82 genomic preCore domains impeding hepatitis B e antigen (HBeAg) production and resembling those observ

83 mutations halt and down-regulate hepatitis B e antigen (HBeAg) production respectively.

84 The durability of hepatitis B e antigen (HBeAg) responses after a consolidation period

85 assess their ability to predict hepatitis B e antigen (HBeAg) seroclearance in patients coinfected w

86 ted death (9.4% vs 0%; P = .03), hepatitis B e antigen (HBeAg) seroconversion (61.5% vs 25.0%, P = .0

87 cts with chronic hepatitis B and hepatitis B e antigen (HBeAg) seroconversion following lamivudine th

88 Their roles in hepatitis B e antigen (HBeAg) seroconversion induced by interferon (

89 It is unclear whether hepatitis B e antigen (HBeAg) seroconversion induced by nucleos(t)id

90 pproved to treat CHB in children.Hepatitis B e antigen (HBeAg) seroconversion is still an important t

91 prolonged viremic phase, delayed hepatitis B e antigen (HBeAg) seroconversion, and an increased incid

92 tion, activity of liver disease, hepatitis B e antigen (HBeAg) seroconversion, and interferon therapy

93 re gene mutations on spontaneous hepatitis B e antigen (HBeAg) seroconversion, HBV biosynthesis, and

94 erferon alfa (IFN-alpha)-related hepatitis B e antigen (HBeAg) seroconversion.

95 In spontaneous hepatitis B e antigen (HBeAg) seroconverters, lower serum HBsAg and

96 Twenty-two percent were hepatitis B e antigen (HBeAg) seropositive; 20.4% (59/289) had cirrh

97 8 and 2022, the annual HBsAg and hepatitis B e antigen (HBeAg) seropositivity rates among native preg

98 ed with respect to HBV genotype, hepatitis B e antigen (HBeAg) serostatus, and race.

99 k prediction model included age, gender, HBV e antigen (HBeAg) serostatus, serum levels of HBV DNA, a

100 Randomisation was stratified by hepatitis B e antigen (HBeAg) status (positive vs negative), HBV DNA

101 identify miRNAs associated with hepatitis B e antigen (HBeAg) status and response to antiviral thera

102 Hepatitis B e antigen (HBeAg) status and serum hepatitis B virus (HB

103 NA viral load, hepatitis surface (HBsAg) and e antigen (HBeAg) status were obtained at baseline and e

104 t of chronic hepatitis B include hepatitis B e antigen (HBeAg) status, levels of hepatitis B virus (H

105 ages, which were predisposed by maternal HBV e antigen (HBeAg) to support HBV persistence by upregula

106 e the usefulness of quantitative hepatitis B e antigen (HBeAg) values for predicting HBeAg seroconver

107 Circulating hepatitis B e antigen (HBeAg) was found to distinguish the group of

108 f hepatitis B virus core antigen (HBcAg) and e antigen (HBeAg) were analyzed.

109 ection who were positive for the hepatitis B e antigen (HBeAg) were randomly assigned (2:1) to receiv

110 endpoint was lack of detectable hepatitis B e antigen (HBeAg) with HBV DNA levels <=1,000 IU/mL 48 w

111 ic T-cell response was weaker in hepatitis B e antigen (HBeAg)(+) than HBeAg(-) patients (percent res

112 atment-experienced children with hepatitis B e antigen (HBeAg)+ CHB were randomized to ADV or placebo

113 titis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and cirrhosis.

114 Hepatitis B e antigen (HBeAg), encoded by the precore RNA, mediates

115 as independently associated with hepatitis B e antigen (HBeAg), HAART <2 years, CD4 <200 cells/mm(3),

116 In contrast to hepatitis B e antigen (HBeAg), HBsAg was not a reliable marker of pr

117 minations were tested for HBsAg, hepatitis B e antigen (HBeAg), serum hepatitis B virus (HBV)-DNA lev

118 ding hepatitis B surface antigen (HBsAg) and e antigen (HBeAg), were tested.

119 (IA), inactive carrier (IC), and hepatitis B e antigen (HBeAg)-negative (ENEG) hepatitis phases-we pe

120 A total of 641 hepatitis B e antigen (HBeAg)-negative and HBeAg-positive patients (

121 ients with the difficult-to-cure hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is

122 Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B infection

123 A total of 1,068 Taiwanese hepatitis B e antigen (HBeAg)-negative HBV carriers with serum HBV D

124 Hepatitis B e antigen (HBeAg)-negative hepatitis is a clinical indic

125 total of 243 (69%) patients were hepatitis B e antigen (HBeAg)-negative of whom 15% had clinical cirr

126 ic patients are responsive, with hepatitis B e antigen (HBeAg)-negative patients responding better th

127 Three cohorts of hepatitis B e antigen (HBeAg)-negative patients were studied: cohort

128 Of the 106 hepatitis B e antigen (HBeAg)-negative patients who entered the TFFU

129 r carcinoma (HCC) development in hepatitis B e antigen (HBeAg)-negative patients with an HBV DNA leve

130 loss in a multicenter cohort of hepatitis B e antigen (HBeAg)-negative patients with chronic hepatit

131 (t)ide analog (Nuc) treatment in hepatitis B e antigen (HBeAg)-negative patients with chronic hepatit

132 cleos(t)ide analogue therapy for hepatitis B e antigen (HBeAg)-negative patients with chronic hepatit

133 HBV) DNA of 203 treatment-naive, hepatitis B e antigen (HBeAg)-negative patients with spontaneous HBs

134 ter variants were more common in hepatitis B e antigen (HBeAg)-negative than in HBeAg-positive patien

135 719 participants, 17 (2.4%) were hepatitis B e antigen (HBeAg)-positive (EP), 620 (86.2%) were classi

136 ucleos(t)ide-naive patients with hepatitis B e antigen (HBeAg)-positive (n = 264) or HBeAg-negative (

137 Hepatitis B e antigen (HBeAg)-positive adults with HBV DNA > 10(7) I

138 copies/mL, <57 IU/mL) in 91% of hepatitis B e antigen (HBeAg)-positive and -negative patients by Wee

139 Approximately 30% of hepatitis B e antigen (HBeAg)-positive and 40% of HBeAg-negative cas

140 imen of pegylated interferon for hepatitis B e antigen (HBeAg)-positive and HBeAg-negative chronic he

141 In hepatitis B e antigen (HBeAg)-positive CHB during NUCs, HBV-infected

142 tures were compared between 38 untreated HBV e antigen (HBeAg)-positive children carrying HBsAg-mutan

143 , multicenter, randomized trial, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) pat

144 nterferon (PEG-IFN) treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) res

145 n nucleoside-naive patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB).

146 limited number of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B respond t

147 to be effective in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, but its

148 une tolerance, immune clearance [hepatitis B e antigen (HBeAg)-positive chronic hepatitis], inactive

149 s given to all 583 children with hepatitis B e antigen (HBeAg)-positive mothers and to 723 of 1773 ch

150 Patients were hepatitis B e antigen (HBeAg)-positive or HBeAg-negative, with level

151 g relatively higher in initially hepatitis B e antigen (HBeAg)-positive patients (62.5%, 53.4%, 51.5%

152 Hepatitis B e antigen (HBeAg)-positive patients achieved a decline o

153 in 14 patients, including 76% of hepatitis B e antigen (HBeAg)-positive patients but only 10% of HBeA

154 Pretransplant HBV E antigen (HBeAG)-positive patients required more HBIG t

155 Fifty-nine hepatitis B e antigen (HBeAg)-positive patients with genotypic evide

156 benefit of antiviral therapy for hepatitis B e antigen (HBeAg)-positive patients with high viral load

157 using nucleoside regimens and in hepatitis B e antigen (HBeAg)-positive patients.

158 Among hepatitis B e antigen (HBeAg)-positive samples, median titers were 4

159 dy compared rates of spontaneous hepatitis B e antigen (HBeAg)-positive to -negative seroconversion i

160 ruited, of which 43 (61.4%) were hepatitis B e antigen (HBeAg)-positive.

161 Three hundred fifty-six hepatitis B e antigen (HBeAg)-seropositive, hepatitis B surface anti

162 ted nonstructural protein called hepatitis B e antigen (HBeAg).

163 ein is secreted from the cell as hepatitis B e antigen (HBeAg).

164 The circulating hepatitis B e antigen (HBeAg, p17) is known to manipulate host immun

165 61 (36.1%) individuals who were hepatitis B "e" antigen (HBeAg) positive at baseline lost HBeAg over

166 anel of HBV serology markers, including HBV "e" antigen (HBeAg), HBV surface antigen (HBsAg), and the

167 Maternal hepatitis B e-antigen (HBeAg) and high viral load have been noted to

168 uch as virologic suppression and hepatitis B e-antigen (HBeAg) or hepatitis B surface antigen loss or

169 HBV e-antigen (HBeAg), a clinical marker for disease severit

170 ction as assembled capsids; and the sentinel e-antigen (HBeAg), a non-particulate form.

171 vely referred to as core antigen (HBcAg) and e-antigen (HBeAg), share a sequence of 149 residues but

172 the most frequent cause of hepatitis B virus e-antigen (HBeAg)-negative chronic hepatitis B virus (HB

173 years, who were treatment naive, hepatitis B e antigen [HBeAg] negative, anti-hepatitis D antigen [HD

174 ed de novo PEG-IFN (n = 299; 195 hepatitis B e antigen [HBeAg] positive) or started PEG-IFN as add-on

175 ions, HBV viral level, change in hepatitis B e antigen [HBeAg] status, genotype, HBV mutations, nonal

176 the secreted nonparticulate form (hepatitis e antigen [HBeAg]).

177 duals with HBsAg clearance by week 72; 3 HBV e antigen [HBeAg]-positive and 4 HBeAg-negative), 7 matc

178 constructs containing wild-type (hepatitis B e antigen [HBeAg]-positive) and precore mutant (HBeAg-ne

179 ency virus or hepatitis B virus (hepatitis B e antigen [HBeAg]-positive) led the Centers for Disease

180 V-related chronic liver disease (hepatitis B e antigen [HBeAg]-positive, n = 11; HBeAg-negative, n =

181 Hepatitis B virus "e-antigen" (HBeAg) is thought to be a soluble dimeric pr

182 ly closed circular DNA transcription and HBV e antigen/HBV surface antigen production, with median in

183 initially positive patients lost hepatitis B e antigen; hepatitis B surface antigen was undetectable

184 evels of neutralizing Abs (NAbs) than the WT E antigen in mice.

185 tected HBV DNA, HBV surface antigen, and HBV e antigen in the serum of experimentally infected animal

186 hematical models for the role of hepatitis B e-antigen in creating immunological tolerance during hep

187 lable that represent both the naive state (i.e. antigen-inexperienced) and that after immunization.

188 , however, is incorrect, because recombinant e-antigen is a stable dimer and its apparent monovalency

189 The e-antigen is often considered to be a monomeric protein

190 pproaches for the isolation of the authentic e-antigen, its biological assay, and its stabilization a

191 -2 positions moderately reduced hepatitis B e antigen levels (P < 0.001) to an extent comparable to

192 r HBV DNA levels, lower rates of hepatitis B e antigen loss, increased cirrhosis and liver-related mo

193 t for mechanisms responsible for hepatitis B e-antigen loss, such as seroconversion and virus mutatio

194 IP-10 or CXCL10) and hepatitis B surface and e antigens might induce these defective pDC functions.

195 positive, and of these, 103/140 (73.6%) were e-antigen negative and 118/140 (84.3%) showed an HBV DNA

196 74-0102 and GS-US-174-0103), 375 hepatitis B e antigen-negative (HBeAg(-) ) patients and 266 HBeAg(+)

197 We analyzed data from 347 hepatitis B e antigen-negative and 238 hepatitis B e antigen positiv

198 K-cell phenotype and function in hepatitis B e antigen-negative chronic HBV patients either untreated

199 Hepatitis B e antigen-negative chronic hepatitis B (e-CHB) has been

200 es in noncirrhotic patients with hepatitis B e antigen-negative chronic hepatitis B.

201 ive mothers and 0.04 (CI, 0.001 to 0.24) for e antigen-negative mothers.

202 ctive HBV carriers, or untreated hepatitis B e antigen-negative patients with chronic infections.

203 In the subgroup of hepatitis B e antigen-negative patients with HBV DNA levels from 200

204 However, when we evaluated hepatitis B e antigen-negative patients with levels of HBV DNA <2000

205 Among hepatitis B e antigen-negative patients with low viral loads, HCC ri

206 In HBV e antigen-negative patients, a lower baseline plasma HBV

207 continuing antiviral therapy in hepatitis B e antigen-negative patients, monotherapy versus adding a

208 The e antigen-negative variant of HBV associated with the G1

209 x mAbs did not discriminate between core and e-antigen, nor did they discriminate between e-antigen a

210 The e antigen of hepatitis B (HBeAg) is positively associate

211 t's antibody reacted preferentially with the e antigen of the Rh system.

212 lization impaired the upregulation of I-Ad/I-Ed antigens on macrophages from infected mice.

213 higher rates of seroconversion (hepatitis B e antigen or hepatitis B surface antigen) compared to si

214 detection of either HBV surface antigen, HBV e antigen, or HBV DNA in serum or plasma any time during

215 positive HBV tests [HBV surface antigen, HBV e antigen, or HBV DNA] >=6 months apart) using American

216 mutation suppresses but does not abolish the e antigen phenotype.

217 In total, 34.6% were hepatitis B e antigen positive (n = 145) and 25.5% had HBV DNA level

218 tis B e antigen-negative and 238 hepatitis B e antigen positive patients receiving tenofovir disoprox

219 icantly higher in those who were hepatitis B e antigen positive, suggesting that antiviral therapy th

220 hepatitis B surface antigen and hepatitis B e antigen positive; 4 had cirrhosis.

221 was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive.

222 ver biopsy specimens of two anti-hepatitis B e antigen-positive (HBe(+)) chronic HBV (CHB) patients.

223 t baseline, 91% of patients were hepatitis B e antigen-positive and 85% had prior exposure to HBV the

224 100 births were 3.37 (CI, 2.08 to 5.14) for e antigen-positive mothers and 0.04 (CI, 0.001 to 0.24)

225 2009 to March 2011, we enrolled hepatitis B e antigen-positive mothers with HBV DNA >6 log10 copies/

226 peripartum antivirals (to 80% of hepatitis B e antigen-positive mothers), and population-wide testing

227 study of 57 treatment-naive patients with HB e antigen-positive or -negative (74%) chronic HBV infect

228 continuing antiviral therapy in hepatitis B e antigen-positive patients who seroconverted from hepat

229 easily detectable in the acute, hepatitis B e antigen-positive phase of infection, suggesting that t

230 s B surface antigen (HBsAg)- and hepatitis B e antigen-positive pregnant women with HBV DNA >/=7.5 lo

231 The management of hepatitis B virus (HBV) e antigen-positive viremic patients with normal liver fu

232 nt was 191 cells/mm3, 44.2% were hepatitis B e antigen-positive, and 28.4% had liver fibrosis/cirrhos

233 age 38 years (range, 18-86), 32% hepatitis B e antigen-positive, median HBV DNA 4.8 log10 IU/mL (unde

234 Maternal hepatitis B e antigen positivity but not hepatitis B immunoglobulin

235 ls of B7-H6 (NCR3LG1); and low levels of HLA-E/antigen presentation genes.

236 n of K562 clones expressing D and G or c and E antigens, respectively.

237 The structure of recombinant e-antigen (rHBeAg) was recently determined, yet to date,

238 s B and chronic hepatitis B with hepatitis B e antigen seroconversion and chronic patients stopping n

239 with YMDD variants, experienced hepatitis B e antigen seroconversion while on lamivudine therapy or

240 f interferon alfa-2b can achieve hepatitis B e antigen seroconversion, normalization of aminotransfer

241 analysis adjusting for age, sex, hepatitis B e antigen serostatus, and diabetes, the presence of NASH

242 ggest that in addition to immunoglobulin (Ig)E, antigen-specific IgG also contributes to the pathogen

243 or beta epitope (in a prior nomenclature for e-antigen specificity).

244 A negative e antigen status or a viral load less than 5 x 107 IU/mL

245 markers of HBV disease activity (hepatitis B e antigen status or HBV DNA level) are associated with H

246 HCC risk include their sex, age, hepatitis B e antigen status, HBV genotype, and levels of alanine am

247 based on age, viral levels, and hepatitis B e antigen status, these clinical and biochemical paramet

248 loads less than 5 x 107 IU/mL, regardless of e antigen status.

249 6379, independently of viral genotype and HB e antigen status.

250 xpressing two configurations of dengue virus E antigen (subviral particles [prME] and soluble E dimer

251 ental approaches to design and produce DENV2 E antigens that are stable homodimers at 37 degrees C an

252 tate its persistence, and use maternal viral e antigen to educate immunity of the offspring to suppor

253 patients who seroconverted from hepatitis B e antigen to hepatitis B e antibody and about the safety

254 her rates of seroconversion from hepatitis B e antigen to hepatitis B e antibody, normalization of al

255 accelerated seroconversion from hepatitis B e antigen to its antibody in black South Africans infect

256 e antigen variants with reduced hepatitis B e antigen translation by a ribosomal leaky scanning mech

257 have identified a novel class of hepatitis B e antigen variants with reduced hepatitis B e antigen tr

258 dimers of the same genotype, and hepatitis B e antigen was quantified from culture medium of transfec

259 Epitope valency of the e-antigen was also studied, using a sandwich SPR assay w

260 so studied, using a sandwich SPR assay where e-antigen was captured with one mAb and probed with a se

261 ore RNA and, consequently, the expression of e antigen were reduced.

262 Both c and E antigens were expressed after transduction of K562 cel

263 COBRA and wild-type E antigens were expressed on the surface of subvirion vi

264 Four separate wild-type E antigens were used for each serotype.

265 HcrAg]) include the WHV core protein and WHV e antigen (WHeAg) as well as the WHV PreC protein (WPreC

266 The precore RNA codes for the secreted e antigen, while the core RNA codes for the major core p